import { ImpactAssessment } from "../models";

export const mockImpactAssessments: ImpactAssessment[] = [
  {
    id: "c4f1a2e7-9b3d-4f8a-8c6e-2a9f7b1d3e45",
    title:
      "New Residency Verification Requirements under Spain-UK Double Taxation Agreement",
    description:
      "The recent update to the Spain-UK Double Taxation Agreement introduces stringent residency verification requirements for individuals claiming tax residency in Spain. Effective immediately, individuals must physically reside in Spain for at least 256 days per calendar year to qualify as residents under the DTA. To substantiate this residency claim, individuals are required to provide daily evidence of their presence in Spain. This includes submitting daily transaction records from Greegs Grocery and daily photographs of themselves walking their dog in a public location, both with verifiable date, time, and location data. These changes are designed to prevent abuse of tax treaty benefits and ensure accurate residency claims.",
  },
  {
    id: "8e6d3c2b-1f4a-4b9d-a7c8-5e2f9d3a6b10",
    title:
      "New Residency Verification Requirements under Spain-UK Double Taxation Agreement",
    description:
      "The recent update to the Spain-UK Double Taxation Agreement introduces stringent residency verification requirements for individuals claiming tax residency in Spain. Effective immediately, individuals must physically reside in Spain for at least 256 days per calendar year to qualify as residents under the DTA. To substantiate this residency claim, individuals are required to provide daily evidence of their presence in Spain. This includes submitting daily transaction records from Greegs Grocery and daily photographs of themselves walking their dog in a public location, both with verifiable date, time, and location data. These changes are designed to prevent abuse of tax treaty benefits and ensure accurate residency claims.",
  },
  {
    id: "3a9d5f2e-7c4b-4e8a-9d1f-6b2c8e5a7f90",
    title:
      "Clarification of Tax Residency Criteria under UK-Spain Double Taxation Agreement",
    description:
      "The recent update to the Spain–United Kingdom Double Taxation Agreement (DTA) involves a clarification of the criteria used to determine tax residency status for individuals. This change affects how individuals can seek relief from double taxation between the UK and Spain. The update specifically addresses the conditions under which an individual is considered a resident of one or both contracting states, impacting Articles related to residency criteria and the elimination of double taxation. This clarification is crucial for ensuring accurate tax reporting and compliance with the DTA's provisions, thereby preventing fiscal evasion and ensuring proper tax liabilities are met in the respective jurisdictions.",
  },

  {
    id: "4a7b8c9e-1f3a-4e2d-9a7b-8c9e1f3a4e2d",
    title: "Impact Assessment: GMP Deviations in Sterile Manufacturing",
    description:
      "This impact assessment evaluates the regulatory and operational implications of repeated Good Manufacturing Practice (GMP) deviations identified in the aseptic filling line at a pharmaceutical production facility. The assessment considers potential risks to product sterility, patient safety, batch release timelines, and regulatory compliance under EU GMP Annex 1. It further examines the likelihood of regulatory inspection findings, required corrective and preventive actions (CAPAs), and the potential impact on manufacturing authorization status if deviations are not effectively remediated.",
  },
  {
    id: "9c2d1f84-6b0a-4eaa-b3d9-2f7c1e8a6b0a",
    title: "Impact Assessment: Data Integrity Risks in GxP IT Systems",
    description:
      "This assessment analyzes the impact of identified data integrity vulnerabilities within computerized systems supporting GxP activities, including laboratory information management systems (LIMS) and manufacturing execution systems (MES). The focus is on compliance with ALCOA+ principles, regulatory expectations from EMA and FDA, and the potential consequences of unauthorized data modification or incomplete audit trails. The assessment outlines risks to product quality decisions, inspection readiness, and the organization’s overall compliance posture.",
  },
  {
    id: "b7f6e9c2-3a4d-4f88-9b6e-1c2a3d4f889b",
    title: "Impact Assessment: Introduction of AI-Based Quality Control Tools",
    description:
      "This impact assessment evaluates the deployment of artificial intelligence-based visual inspection tools within pharmaceutical quality control processes. It considers regulatory expectations for validation, transparency, and human oversight, as well as alignment with GAMP 5 and emerging EU AI Act requirements. The assessment identifies risks related to algorithm bias, model drift, explainability, and reliance on automated decision-making in batch disposition, along with mitigation strategies to ensure continued regulatory acceptance.",
  },
  {
    id: "e1a4c7b9-2d6f-4c5a-8e1a-4c7b92d6f4c5",
    title:
      "Impact Assessment: EU AI Act Classification of Clinical Decision Support Systems",
    description:
      "This assessment examines whether a clinical decision support system used in pharmaceutical research and development qualifies as a high-risk AI system under the EU AI Act. It evaluates system functionality, intended use, and potential impact on patient outcomes. The analysis covers obligations related to risk management, data governance, technical documentation, post-market monitoring, and conformity assessment, as well as the operational and compliance impact of meeting these requirements.",
  },
  {
    id: "3d9a7e2b-5c1f-4d88-b3d9-a7e2b5c1f4d8",
    title:
      "Impact Assessment: Supply Chain Disruptions and Regulatory Compliance",
    description:
      "This impact assessment focuses on the regulatory and quality implications of supply chain disruptions affecting active pharmaceutical ingredient (API) sourcing. It evaluates risks related to supplier qualification, change control, regulatory filings, and continuity of supply. The assessment also considers the potential need for regulatory notifications or variations, the impact on product availability, and mitigation measures to maintain compliance during prolonged disruptions.",
  },
  {
    id: "f2c8a1d4-9b6e-4a3c-8f2c-8a1d49b6e4a3",
    title: "Impact Assessment: Automated Decision-Making in Pharmacovigilance",
    description:
      "This assessment analyzes the use of automated signal detection and case prioritization tools in pharmacovigilance activities. It considers regulatory expectations for transparency, human oversight, and validation under GVP and the EU AI Act. The assessment identifies risks related to missed safety signals, over-reliance on automated outputs, and accountability for regulatory reporting decisions, along with controls to ensure compliant and effective safety monitoring.",
  },
  {
    id: "6e5d3c2b-1a9f-4b6e-9d3c-5d3c2b1a9f4b",
    title:
      "Impact Assessment: Cross-Border Data Transfers in Regulated AI Systems",
    description:
      "This impact assessment evaluates the compliance implications of transferring regulated data used by AI systems across jurisdictions, particularly between the EU and third countries. It considers GDPR requirements, EU AI Act obligations, and sector-specific regulations relevant to pharmaceutical operations. The assessment addresses risks related to data protection, regulatory scrutiny, and enforcement actions, as well as technical and organizational safeguards required to mitigate these risks.",
  },
];
